þ stem/progenitor cells appear resistant to imatinib mesylate (IM) in vitro and in vivo. To investigate the underlying mechanism(s) of IM resistance, it is essential to quantify Bcr-Abl kinase status at the stem cell level. We developed a flow cytometry method to measure CrkL phosphorylation (P-CrkL) in samples with o10 4 cells. The method was first validated in wild-type (K562) and mutant (BAF3) BCR-ABL þ as well as BCR-ABL À (HL60) cell lines. In response to increasing IM concentration, there was a linear reduction in P-CrkL, which was Bcr-Abl specific and correlated with known resistance. The results were comparable to those from Western blotting. The method also proved to be reproducible with small samples of normal and Ph þ CD34
Introduction
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of haemopoietic stem cells, characterised by the reciprocal translocation between chromosomes 9 and 22. 1 This translocation generates the oncogenic bcr-abl fusion gene, which encodes a protein that demonstrates higher and constitutively active tyrosine kinase activity compared with the normal Abl counterpart. 2 Although Bcr-Abl is known to play a central role in the pathogenesis of CML, the specific mechanisms by which it mediates the disease are still unclear. However, there is evidence that it induces tyrosine phosphorylation of downstream signalling substrates, including CrkL. CrkL is the major tyrosyl-phosphoprotein detected in the peripheral blood cells of patients with CML, suggesting that its association with Bcr-Abl plays an important role in the pathogenesis of the disease. [3] [4] [5] The specificity of CrkL phosphorylation to Bcr-Abl signalling, partnered with the stability of the phosphoprotein complex, has led to its acceptance as an excellent method to assess Bcr-Abl status. 6, 7 CrkL phosphorylation has previously been determined by Western blot in Bcr-Abl-expressing cell lines and primary CML cells; however, this method is time consuming and requires large numbers of cells, which are difficult to obtain from primary cell samples. As part of our efforts to characterise CML stem cells, [8] [9] [10] [11] we have now developed a method to detect phosphorylated CrkL by flow cytometry, using an anti-phospho-CrkL (P-CrkL) antibody, requiring minimal cell numbers from patient samples.
Materials and methods

Reagents
Imatinib mesylate (IM) was a gift from Novartis Pharma (Basle, Switzerland).
Cell lines
The BCR-ABL-positive K562 and BCR-ABL-negative HL60 cell lines were grown in suspension in RPMI 1640 (Sigma-Aldrich Company Ltd, Dorset, UK) with 10% fetal calf serum (Invitrogen, Paisley, UK), 1% glutamine (100 mM) and 1% penicillinstreptomycin (100 mM) (Invitrogen) (RPMI þ ), in a humidified incubator at 371C in an atmosphere of 5% (v/v) CO 2 . Every 3-4 days, cells were counted using a haemocytometer and set up at 1 Â 10 6 cells per 75 cm 2 flask with fresh RPMI þ . BA/F3 cells containing wild-type or Bcr-Abl with kinase domain mutations were maintained in RPMI þ supplemented with 10% conditioned medium from WEHI-3B cells.
Primary cell samples of fresh leukapheresis products from patients with chronic-phase CML, before any exposure to IM in vivo, or from patients undergoing autologous stem cell transplantation, were enriched for CD34 þ cells using a clinical scale method of magnetic-activated cell sorting -CLINIMACS (Miltenyi Biotec Ltd, Bisley, UK). The selected cells were then cryopreserved in 10% (v/v) dimethyl sulfoxide in ALBA (4% (w/v) Human Albumin Solution, Scottish National Blood Transfusion Service, Edinburgh, UK) and stored in the vapour phase of liquid nitrogen until required. All human cell samples were obtained with informed consent. Cells were cultured in Iscove's modified Dulbecco's medium (Sigma) supplemented with a serum substitute (BIT; StemCell Technologies, Vancouver, Canada), 0.1 mM 2-mercaptoethanol (Sigma), 1% glutamine (100 mM) and 1% penicillin-streptomycin (100 mM) (serum-free medium, SFM). Serum-free medium was further supplemented with a five growth factor cocktail comprising 100 ng/ml Flt3-ligand and 100 ng/ml stem cell factor and 20 ng/ml each of interleukin (IL)-3, IL-6 (all from StemCell Technologies) and granulocyte colony stimulating factor (Chugai Pharma Europe Ltd, London, UK). 
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A Hamilton et al 15 min, washed with 3 ml phosphate-buffered saline (PBS)/1% bovine serum albumin (BSA)/0.1% sodium azide and centrifuged at 1000 rpm for 5 min. Twenty-five microlitres of Permeablising Reagent (CALTAG Laboratories) were added to the cell pellet with 2.5 ml of P-CrkL-specific antibody (New England Biolabs (UK) Ltd, Hitchin, UK) and the cells were vortexed and incubated at RT for 40 min. The wash step was repeated twice, the cells were re-suspended in 100 ml PBS/BSA/ sodium azide and the secondary antibody (anti-rabbit IgG FITCconjugate (Sigma)) and incubated at RT for 30 min in the dark. The wash step was repeated twice and the samples were analysed by flow cytometry. Isotype controls were included for cytometer set-up. The assay was also run on fresh compared to cryopreserved aliquots of the same samples to confirm that P-CrkL baseline levels were unchanged by cryopreservation (data not shown).
The amount of P-CrkL in the sample was determined as the geometric mean fluorescence intensity (MFI) of the P-CrkLlabelled untreated sample minus the MFI of the BCR-ABLnegative control (baseline P-CrkL). The P-CrkL status of the IMtreated samples was expressed as a percentage of the untreated control (100%).
K562 Western blot and HL60 were cultured in the presence or absence of IM for 48 h. CD34
þ CML cells were cultured in the presence or absence of IM for 16 and 72 h. Western blot was performed using standard techniques with the same specific anti-P-CrkL primary antibody (1:1000) (New England Biolabs) as used in flow cytometry and an anti-rabbit IgG, horseradish peroxidase-linked secondary antibody (1:3000) (New England Biolabs). The membranes were then stripped in 1 Â 'Re-Blot Plus Strong Antibody Stripping Solution' (Chemicon, Hampshire, UK) for 15 min at RT and re-probed with anti-pan-actin antibody (1:1000) (New England Biolabs) in 5% BSA/phosphatebuffered saline with BSA, to confirm equal sample loading. Developed films were scanned with an Epson scanner and the integrated density of protein bands was determined with ImageQuant software (Molecular Dynamics). Densitometry data were normalised so that the untreated control had 100% P-CrkL and the result from each IM-treated sample was calculated based on this.
Results and discussion
Effect of IM on CrkL phosphorylation in K562, HL60 and BAF3-BCR-ABL cells
In order to determine Bcr-Abl kinase status in response to IM treatment in rare stem cell populations, we first validated an intracellular flow cytometry assay measuring P-CrkL in the BCR-ABL-positive cell line K562 and the BCR-ABL-negative cell line HL60. IM treatment of HL60 cells had no effect on baseline P-CrkL status at either 16 or 48 h (Figure 1a) . Figure 1b and its corresponding MFI data presented in Table 1 show that IMtreated K562 cells demonstrated a dose-dependent decrease of P-CrkL, with only 16.6% phosphorylation after 48 h treatment with 10 mM IM, as compared to no drug control (100%). To prove the specificity of the P-CrkL antibody in the flow cytometry-based detection method, the effect of IM on P-CrkL was also assessed by Western blot on K562, HL60 and CML CD34 þ cells. Abbreviations: IM, imatinib mesylate; MFI, mean fluorescence intensity.
BCR-ABL activity and P-CrkL status in CML stem cells A Hamilton et al CD34 þ protein level (actin loading control) at 72 h was lower owing to the decrease in overall cell number. P-CrkL expression was not evident in HL60 cells.
We next investigated how cell lines with verified resistant phenotypes would perform in this assay. BAF3-BCR-ABL wild type, M351T (low-level IM resistance), H396P (intermediate IM resistance) and T315I (high IM resistance) were compared for P-CrkL inhibition at 16 h after IM exposure. As shown in Figure 2 , the individual cell lines could be identified by their differing degrees of resistance as was expected from their known mutations. 13 
Effect of IM treatment on primary CD34
þ CML cells
Previous investigators have demonstrated the differences in total phosphotyrosine inhibition between CD34 þ cells from cytogenetic responders and non-responders to IM treatment.
14 Therefore, to more directly assess Bcr-Abl kinase activity in response to IM treatment, we cultured CD34 þ cells from normal donors and CML patients (n ¼ 8) in the presence and absence of 5 mM IM for 72 h. P-CrkL was measured at 16 h to determine the immediate effects on P-CrkL, and at 72 h, in order to examine the P-CrkL status in those cells that survived drug treatment. Figure 3a demonstrates the P-CrkL profile of the only CML patient in this series of eight who did not respond optimally to IM treatment (i.e. did not achieve cytogenetic response by 6 months). After both 16 and 72 h, IM-treated CD34 þ CML cells showed no reduction in P-CrkL, consistent with the presence of IM-resistant cells. We were unable to demonstrate the presence of a known IM resistance mutation for this case at diagnosis using direct sequencing, consistent with the literature, 15, 16 and by Double-fluorescent in situ hybridisation, there was no evidence of BCR-ABL amplification, either in the starting population of CD34 þ cells or after drug exposure. Figure 3b shows a representative P-CrkL profile of a CML patient who responded well to IM treatment (i.e. complete haematological remission by 4 weeks and complete cytogenetic remission by 6 months). This was the pattern seen for seven of the eight cases. After 16 h, there was only 7% phosphorylation of CrkL in IMtreated CD34
þ CML cells, relative to no drug control (100%), indicating that most of the cells were sensitive to IM. However, after the 72 h time point, the cells that had survived IM treatment demonstrated a return to baseline of P-CrkL. This suggests that following the death of IM-susceptible CD34 þ CML cells, there was enrichment for an IM-resistant cell population. Figures 3c-e demonstrate the heterogeneity of response to IM treatment in CD34 þ CML cells. Rather than producing the expected single P-CrkL peak, in the absence of IM, three different peaks were evident in this profile, suggesting the presence of three cell populations within the CML sample (Figure 3c ). This patient was diagnosed early with total WBC of only 18 Â 10 9 /l. Baseline cytogenetics confirmed a significant proportion (40%) of Ph À metaphases. Following IM treatment, a clear population shift was evident (Figure 3d ). The population with medium intensity antibody staining (**) after exposure to IM was IM responsive, with significant reduction in P-CrkLs from baseline, relative to the untreated control (Figure 3c ). It is probable that the population denoted (***) therefore represented normal Ph À
CD34
þ cells, whereas the cells with highest intensity staining (*) proved to be IM resistant.
Overall, these results validate a rapid method to detect P-CrkL protein at the single cell level by flow cytometry. The minimum number of cells may be reduced to o10 4 for test and control, enabling an accurate assessment of Bcr-Abl kinase activity in rare stem cell populations in response to novel tyrosine kinase inhibitors.
